CPC G01N 33/6854 (2013.01) [G01N 2333/205 (2013.01); G01N 2800/065 (2013.01); G01N 2800/52 (2013.01)] | 18 Claims |
1. A method of detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin (CDT), CdtA, CdtB, CdtC, or a fragment thereof, comprising:
obtaining a biological sample from a subject having a symptom of post-infectious irritable bowel syndrome (PI-IBS);
detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin (CDT), CdtA, CdtB, CdtC, or a fragment thereof in an enzyme-linked immunosorbent assay (ELISA), immunohistochemistry, flow cytometry, a radioimmuno assay, or affinity purification, by contacting CDT, CdtA, CdtB, CdtC, or a fragment thereof, to the biological sample and detecting a signal that indicates the presence of the antibody capable of binding to CDT, CdtA, CdtB, CdtC, or a fragment thereof.
|
16. A method of detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin B (CdtB) of Campylobacter jejuni or a fragment thereof, comprising:
obtaining whole blood, plasma or serum from a subject having a symptom of post-infectious irritable bowel syndrome (PI-IBS);
detecting the presence or absence of an antibody capable of binding specifically to cytolethal distending toxin B (CdtB) of Campylobacter jejuni or a fragment thereof in an enzyme-linked immunosorbent assay (ELISA) by contacting CdtB of Campylobacter jejuni or a fragment thereof to the whole blood, plasma or serum and detecting a signal that indicates the presence of the antibody capable of binding to CdtB of Campylobacter jejuni or the fragment thereof.
|